MOESM2 of Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

Descripció

Additional file 2. This file includes all the references screened in the systematic review and the reason for exclusion.

Data disponible	22 d’oct. 2019
Editor	figshare

DOI
10.6084/m9.figshare.10022105

1 Article

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
Sampayo-Cordero, M., Miguel-Huguet, B., Pardo-Mateos, A., Malfettone, A., Pérez-García, J., Llombart-Cussac, A., Cortés, J., Moltó-Abad, M., Muñoz-Delgado, C., Pérez-Quintana, M. & Pérez-López, J., 21 d’oct. 2019, In: Orphanet Journal of Rare Diseases. 14, 1, 230.
Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

Accés Obert
18 Cites (Scopus)

Com citar-ho

Sampayo-Cordero, M. (Creador), Miguel-Huguet, B. (Col·laborador), Pardo-Mateos, A. (Creador), Malfettone, A. (Creador), Pérez Garcia, J. I. (Creador), Llombart-Cussac, A. (Creador), Cortés, J. (Creador), Moltó-Abad, M. (Creador), Muñoz-Delgado, C. (Creador), Pérez-Quintana, M. (Creador), Pérez-López, J. (Creador) (22 d’oct. 2019). MOESM2 of Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. figshare. 10.6084/m9.figshare.10022105